PROGRAF 1 mg capsule

DRUG6 trials

Sponsors

Oslo University Hospital HF, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Universitair Medisch Centrum Groningen, Centre Hospitalier Universitaire De Nantes

Conditions

Kidney transplantationOrgan transplantationdiabetic patients pancreatic transplantlung transplantationpediatric kidney transplant recipients

Phase 1

IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO)

Not yet recruitingCTIS2025-524834-24-00

Centre Hospitalier Universitaire De Nantesdiabetic patients pancreatic transplant

Target: 15Updated: 2026-03-12

Phase 3

REVOLUTION; Randomized controlled trial comparing immediate versus extended release tacrolimus; reducing calcineurin inhibitor related toxicity in lung transplantation patients

Not yet recruitingCTIS2024-518639-12-00

Universitair Medisch Centrum Groningenlung transplantation

Target: 140Updated: 2025-01-28

Phase 4

Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects

Not yet recruitingCTIS2023-510486-10-00

Oslo University Hospital HFKidney transplantation

Target: 100Updated: 2024-05-22

Personalized tacrolimus treatment for pediatric kidney transplant recipients by using a dosing algorithm and a once-daily tacrolimus formulation

Not yet recruitingCTIS2024-511585-36-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)pediatric kidney transplant recipients

Target: 28Updated: 2024-06-28

CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS

Not yet recruitingCTIS2024-515164-30-00

Oslo University Hospital HFKidney transplantation

Target: 26Updated: 2024-09-25

Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept

Not yet recruitingCTIS2025-521800-22-00

Oslo University Hospital HFOrgan transplantation

Target: 27Updated: 2025-07-04